Therapeutic | Tildrakizumab |
Target | IL23A |
Heavy Chain | QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2012 |
INN Year Recommended | 2013 |
Companies Involved | Almirall S.A., Merck & Co, Schering-Plough, Sun Pharmaceutical Industries |
Conditions Approved | Plaque psoriasis |
Conditions Active | Ankylosing spondylitis, Intervertebral disc degeneration, Non-radiographic axial spondyloarthritis, Psoriatic arthritis |
Conditions Discontinued | Autoimmune disorders |
Notes |